Health & bio
FDA Approves Langlara Insulin Glargine Biosimilar
On April 29, the FDA approved insulin glargine-aldy (Langlara), a Lantus-compatible biosimilar for long-acting insulin treatment of diabetes.
Primary sources · 1
On April 29, the FDA approved insulin glargine-aldy (Langlara), a Lantus-compatible biosimilar for long-acting insulin treatment of diabetes.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.